LeMaitre Vascular (NASDAQ:LMAT) Cut to Hold at StockNews.com

StockNews.com cut shares of LeMaitre Vascular (NASDAQ:LMAT) from a buy rating to a hold rating in a report issued on Thursday morning.

Several other research analysts have also recently commented on the stock. Lake Street Capital assumed coverage on shares of LeMaitre Vascular in a report on Friday, August 2nd. They set a “buy” rating and a $105.00 price target for the company. JMP Securities increased their target price on LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a report on Tuesday, August 20th. Barrington Research raised their price target on LeMaitre Vascular from $92.00 to $93.00 and gave the company an “outperform” rating in a research note on Friday, November 1st. Oppenheimer reaffirmed an “outperform” rating and set a $93.00 price objective (up from $90.00) on shares of LeMaitre Vascular in a research report on Friday, November 1st. Finally, Cantor Fitzgerald initiated coverage on LeMaitre Vascular in a research report on Tuesday, October 15th. They set a “neutral” rating and a $96.00 target price on the stock. Three analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $94.57.

LeMaitre Vascular Trading Up 2.0 %

NASDAQ:LMAT opened at $107.97 on Thursday. LeMaitre Vascular has a 12-month low of $51.70 and a 12-month high of $108.09. The firm has a market cap of $2.43 billion, a PE ratio of 59.00, a price-to-earnings-growth ratio of 2.59 and a beta of 0.89. The stock has a fifty day moving average price of $93.85 and a 200 day moving average price of $86.91.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.05. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The business had revenue of $54.82 million during the quarter, compared to analysts’ expectations of $53.50 million. During the same quarter last year, the business posted $0.33 EPS. The business’s quarterly revenue was up 15.6% compared to the same quarter last year. Equities analysts forecast that LeMaitre Vascular will post 1.94 EPS for the current year.

LeMaitre Vascular Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 5th. Investors of record on Thursday, November 21st will be given a $0.16 dividend. The ex-dividend date is Thursday, November 21st. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.59%. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 34.97%.

Insider Buying and Selling

In related news, Director Bridget A. Ross sold 3,750 shares of the stock in a transaction on Friday, November 15th. The shares were sold at an average price of $101.47, for a total transaction of $380,512.50. Following the completion of the sale, the director now owns 2,278 shares in the company, valued at $231,148.66. This represents a 62.21 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 10.79% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Conestoga Capital Advisors LLC grew its holdings in shares of LeMaitre Vascular by 1.9% during the third quarter. Conestoga Capital Advisors LLC now owns 1,978,351 shares of the medical instruments supplier’s stock worth $183,769,000 after buying an additional 36,850 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of LeMaitre Vascular by 0.3% in the 1st quarter. Vanguard Group Inc. now owns 1,553,834 shares of the medical instruments supplier’s stock valued at $103,112,000 after purchasing an additional 4,964 shares during the last quarter. Copeland Capital Management LLC increased its holdings in shares of LeMaitre Vascular by 1.0% in the third quarter. Copeland Capital Management LLC now owns 1,163,392 shares of the medical instruments supplier’s stock valued at $108,068,000 after purchasing an additional 11,318 shares during the period. State Street Corp raised its stake in shares of LeMaitre Vascular by 3.6% during the third quarter. State Street Corp now owns 822,085 shares of the medical instruments supplier’s stock worth $76,363,000 after purchasing an additional 28,525 shares during the last quarter. Finally, Congress Asset Management Co. lifted its holdings in shares of LeMaitre Vascular by 2.6% during the third quarter. Congress Asset Management Co. now owns 709,316 shares of the medical instruments supplier’s stock worth $65,888,000 after purchasing an additional 18,295 shares during the period. 84.64% of the stock is currently owned by institutional investors and hedge funds.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.